Evidence map›Paper›PMID 39934309›Full record

ArticleScientific reports2025

ZCCHC4 regulates esophageal cancer progression and cisplatin resistance through ROS/c-myc axis.

Lihua Yao, Piao Wu, Fangyi Yao, Bo Huang, Fangmin Zhong, Xiaozhong Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Multi-omics analysis reveals that knockdown of IMPA2 induces apoptosis in cervical cancer cells through ROS/MYC/CDK1 signaling.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. mFrontiers in cell and developmental biology · 2026
    Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lihua Yao *Department of Clinical Laboratory, Affiliated Hospital of North Sichuan Medical College, School of Clinical Medicine, North Sichuan Medical College, Nanchong, 637000, Sichuan, China.
Piao Wu *Department of Clinical Laboratory, Affiliated Hospital of North Sichuan Medical College, School of Clinical Medicine, North Sichuan Medical College, Nanchong, 637000, Sichuan, China.
Fangyi YaoJiangxi Province Key Laboratory of Immunology and Inflammation, Jiangxi Provincial Clinical Research Center for Laboratory Medicine, Department of Clinical Laboratory, The Second Affiliated Hospital, Jiangxi Medical College, , Nanchang University, Nanchang, 330006, China.
Bo HuangJiangxi Province Key Laboratory of Immunology and Inflammation, Jiangxi Provincial Clinical Research Center for Laboratory Medicine, Department of Clinical Laboratory, The Second Affiliated Hospital, Jiangxi Medical College, , Nanchang University, Nanchang, 330006, China.
Fangmin ZhongJiangxi Province Key Laboratory of Immunology and Inflammation, Jiangxi Provincial Clinical Research Center for Laboratory Medicine, Department of Clinical Laboratory, The Second Affiliated Hospital, Jiangxi Medical College, , Nanchang University, Nanchang, 330006, China. 1332721102@qq.com.
Xiaozhong WangJiangxi Province Key Laboratory of Immunology and Inflammation, Jiangxi Provincial Clinical Research Center for Laboratory Medicine, Department of Clinical Laboratory, The Second Affiliated Hospital, Jiangxi Medical College, , Nanchang University, Nanchang, 330006, China. xzhongwang2022@163.com.

Funding

National Natural Science Foundation of China 82160405Science and Technology Plan of Jiangxi Province 20213BCJ22013
6 · The paper itself

Abstract

Zinc finger CCHC-type containing 4 (ZCCHC4) is a newly discovered N

Indexed as

CisplatinDrug Resistance, NeoplasmEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaProto-Oncogene Proteins c-mycReactive Oxygen SpeciesAnimalsAntineoplastic AgentsApoptosisCell Line, TumorCell ProliferationDisease ProgressionFemaleGene Expression Regulation, NeoplasticHumansMaleAntineoplastic AgentsCisplatinMYC protein, humanProto-Oncogene Proteins c-mycReactive Oxygen SpeciesCisplatin resistanceC-mycEsophageal cancerRNA-binding proteinZCCHC4

Identifiers

PMID39934309
PMCPMC11814405

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.